SYNACT — SynAct Pharma AB Income Statement
0.000.00%
Last trade - 00:00- SEK236.72m
- SEK174.97m
Annual income statement for SynAct Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | SAS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 24.8 | 31.3 | 76.7 | 106 | 224 |
| Operating Profit | -24.8 | -31.3 | -76.7 | -106 | -224 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -27.1 | -31.3 | -76.8 | -107 | -224 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -24 | -26.6 | -69.3 | -99.2 | -216 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -24 | -26.6 | -69.3 | -99.2 | -216 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -24 | -26.6 | -69.3 | -99.2 | -216 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.62 | -1.04 | -2.67 | -3.6 | -4.93 |
| Dividends per Share |